Gamma oscillatory power is impaired during cognitive control independent of medication status in first-episode schizophrenia.
Schizophrenia is characterized by impaired cognitive control associated with prefrontal cortex dysfunction, but the underlying pathophysiological mechanisms remain unknown. Higher cognitive processes are associated with cortical oscillations in the gamma range, which are also impaired in chronic schizophrenia. We tested whether cognitive control-related gamma deficits are observed in first-episode patients, and whether they are associated with antipsychotic medication exposure. Fifty-three first-episode schizophrenia patients (21 without antipsychotic medication treatment) and 29 healthy control subjects underwent electroencephalography (EEG) during performance of a preparatory cognitive control task (preparing to overcome prepotency or POP task). The first-episode schizophrenia patient group was impaired (relative to the control group) on task performance and on delay-period gamma power at each of the three subgroups of frontal electrodes. The unmedicated patient subgroup was similarly impaired compared with controls, and was not different on these measures compared with the medicated patient subgroup. In contrast, delay-period theta power was not impaired in the full patient group nor in the unmedicated patient subgroup. Impaired cognitive control-related gamma cortical oscillatory activity is present at the first psychotic episode in schizophrenia, and is independent of medication status. This suggests that altered local circuit function supporting high-frequency oscillatory activity in prefrontal cortex ensembles may serve as the pathophysiological substrate of cognitive control deficits in schizophrenia.
Minzenberg
Michael J
MJ
Department of Psychiatry, University of California, Davis School of Medicine, Sacramento, CA 95817, USA. michael.minzenberg@ucdmc.ucdavis.edu
Firl
Alana J
AJ
Yoon
Jong H
JH
Gomes
Glenn C
GC
Reinking
Celeste
C
Carter
Cameron S
CS
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001931:Brain Mapping / Q000379:methods; D058256:Brain Waves / Q000187:drug effects / Q000502:physiology*; D002540:Cerebral Cortex / Q000502:physiology / Q000503:physiopathology; D003071:Cognition / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D011597:Psychomotor Performance / Q000502:physiology; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents
Neuroscientist. 2003 Dec;9(6):475-84
14678580
Am J Psychiatry. 2005 Dec;162(12):2322-9
16330597
Biol Psychiatry. 2008 Apr 15;63(8):744-7
18083143
Am J Psychiatry. 2003 Dec;160(12):2238-40
14638599
Biol Psychiatry. 2008 Sep 1;64(5):369-75
18400208
J Neurosci Methods. 2004 Mar 15;134(1):9-21
15102499
Trends Cogn Sci. 2004 Aug;8(8):347-55
15335461
Int J Psychophysiol. 2007 Apr;64(1):39-45
16962192
Brain Res Cogn Brain Res. 2005 Dec;25(3):936-47
16289526
J Neuropathol Exp Neurol. 2008 Jun;67(6):543-54
18520773
Psychiatry Res. 2006 Jan 30;141(1):53-60
16343645
Science. 2005 Aug 5;309(5736):951-4
16081741
Am J Psychiatry. 2005 Mar;162(3):475-84
15741464
Neuroimage. 2005 Aug 15;27(2):341-56
15927487
Pharmacol Ther. 2000 May;86(2):171-90
10799713
Trends Neurosci. 2005 Nov;28(11):602-10
16139371
Schizophr Res. 2004 Oct 1;70(2-3):293-302
15329305
Trends Cogn Sci. 1999 Apr;3(4):151-162
10322469
Am J Psychiatry. 2005 Dec;162(12):2330-6
16330598
Nat Rev Neurosci. 2001 Oct;2(10):704-16
11584308
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17288-93
15546988
Biol Psychiatry. 1999 Jan 1;45(1):17-25
9894571
Arch Gen Psychiatry. 1999 Nov;56(11):1001-5
10565499
Am J Psychiatry. 1996 Mar;153(3):321-30
8610818
Mod Probl Pharmacopsychiatry. 1974;7(0):1-7
4153453
Neuroimage. 2008 Oct 1;42(4):1481-9
18634887
Clin Neurophysiol. 2000 Aug;111(8):1461-8
10904228
Neuron. 2002 Jan 31;33(3):325-40
11832222
Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19878-83
17170134
Clin Neurophysiol. 2000 Nov;111(11):2079-87
11068245
Am J Psychiatry. 2004 Sep;161(9):1595-602
15337649
J Neurosci. 2006 Aug 2;26(31):8168-75
16885230
Trends Neurosci. 2003 Sep;26(9):489-95
12948660
Schizophr Bull. 2008 Sep;34(5):944-61
18586694
Brain Res Brain Res Rev. 2003 Jan;41(1):57-78
12505648
Am J Psychiatry. 2008 Aug;165(8):996-1005
18483133
Biol Psychiatry. 2001 Dec 1;50(11):825-44
11743939
Science. 1995 Mar 10;267(5203):1512-5
7878473
Am J Psychiatry. 2005 Oct;162(10):1833-9
16199829
Am J Psychiatry. 2008 Dec;165(12):1585-93
18923067
Nat Rev Drug Discov. 2004 Apr;3(4):353-9
15060530
Neuroreport. 2004 Jan 19;15(1):155-9
15106849
J Abnorm Psychol. 1999 Feb;108(1):120-33
10066998
J Abnorm Psychol. 2003 Nov;112(4):689-97
14674880
J Neurosci. 2003 Aug 13;23(19):7407-11
12917376
Arch Neurol. 2006 Oct;63(10):1372-6
17030651
Nature. 2001 Jul 12;412(6843):150-7
11449264
Schizophr Bull. 2008 Sep;34(5):907-26
18684772
Schizophr Bull. 2008 Sep;34(5):927-43
18562344
Am J Psychiatry. 2008 Aug;165(8):1006-14
18519527
J Neurosci. 2010 Mar 10;30(10):3777-81
20220012
Schizophr Res. 2005 Jul 15;76(2-3):199-206
15949653
Neuroimage. 2009 Oct 1;47(4):1711-9
19371786
Biol Psychiatry. 2008 Apr 15;63(8):736-43
17981264
Biol Psychiatry. 2006 Dec 1;60(11):1231-40
16893524
Arch Gen Psychiatry. 2009 Aug;66(8):811-22
19652121
Clin Neurophysiol. 2004 Aug;115(8):1863-74
15261865
Biol Psychiatry. 2003 Jan 1;53(1):25-38
12513942
Arch Gen Psychiatry. 2001 Mar;58(3):280-8
11231835
Am J Psychiatry. 2005 Mar;162(3):459-65
15741462
Am J Psychiatry. 2001 Sep;158(9):1423-8
11532726